Research & Emerging Evidence

Evidence reviewed through:

⚕️ This article is education, not medical advice. Every claim is sourced below. Never stop or change medication without your prescriber — some medications are dangerous to stop abruptly.

DORAs in 2026: How Quviviq, Dayvigo, and Belsomra Differ

Key answer

Daridorexant (Quviviq), lemborexant (Dayvigo), and suvorexant (Belsomra) share dual orexin receptor antagonism but differ in approved doses, pharmacokinetics, trial programs, interaction language, and regional labeling; no network estimate makes one universally best. The practical interpretation must remain within the population, duration, formulation, and outcomes that were actually studied. [1–3]

A safe interpretation starts with the exact medication or intervention, the reason it is being used, the formulation, treatment duration, other medicines, current symptoms, and the risks of both continuing and changing treatment. The article therefore explains decision factors and safety boundaries rather than prescribing a fixed schedule.

At a glance

Question or decisionEvidence-based answer
One-sentence findingDaridorexant (Quviviq), lemborexant (Dayvigo), and suvorexant (Belsomra) share dual orexin receptor antagonism but differ in approved doses, pharmacokinetics, trial programs, interaction language, and regional labeling; no network estimate makes one universally best. [1–3]
Evidence baseThe core evidence consists of regulator-hosted prescribing information, placebo-controlled insomnia trials, extension studies, and systematic reviews or network meta-analyses. Labels provide the most reliable product-specific details. Network meta-analysis can compare treatments indirectly across different trials, but differences in participants, outcome definitions, dose, timing, and study duration reduce certainty. [1–3]
Main uncertaintyThere are few direct head-to-head randomized comparisons. Trials often exclude severe sleep apnea, unstable psychiatric illness, substance-use disorders, complex polypharmacy, pregnancy, and many frail patients. Most outcomes are short term compared with years of real-world use. Indirect rank probabilities can exaggerate small, uncertain differences and should not be converted into “best DORA” claims. [1–3]
Practice implicationBuild a product comparison from current labels with columns for generic name, region, approved indication, dose range, CYP3A restrictions, half-life context, next-day precautions, and studied populations. Pair that with first-line CBT-I information. The final choice belongs to the prescriber and patient after reviewing comorbidities and goals. [1–3]
Not justifiedThe evidence does not justify substituting one DORA for another milligram-for-milligram, promising no next-day impairment, declaring a class-wide absence of withdrawal, or recommending a DORA solely because it ranks first in an indirect analysis. [1–3]
How to interpret DORA evidence without overclaiming
How to interpret DORA evidence without overclaiming. A map separating product-label findings, controlled-trial conditions, real-world uncertainty, and patient-specific decisions.

Evidence basis and uncertainty

This article prioritizes regulator-hosted product information, current clinical guidance, systematic reviews, randomized trials, and carefully labeled observational or mechanistic evidence. The references below are used according to their design and limitations [1–3]. Absence of a detected signal is not rewritten as absence of risk, and a population average is not presented as an individual prediction.

ReferenceEvidence typeHow it is used in this article
1Regulator-hosted product labelingTrial-based withdrawal and rebound assessments must not be rewritten as universal absence of risk.
2Network meta-analysisIndirect comparisons are not equivalent to head-to-head trials and must be interpreted with dose, duration, and outcome differences.
3Clinical practice guidelineStrongly recommends multicomponent CBT-I for chronic insomnia; sleep hygiene alone is not equivalent to CBT-I.

Working definitions

TermMeaning in this article
Withdrawal symptomsNew or intensified symptoms after a dose reduction, missed dose, formulation change, or stop when physiologic adaptation is a plausible contributor.
ReboundTemporary return of a treated symptom above its pretreatment baseline.
Relapse or recurrenceReturn of the underlying treated condition.
Physical dependencePhysiologic adaptation; it is not the same as addiction or a substance use disorder.

The finding in one sentence

Daridorexant (Quviviq), lemborexant (Dayvigo), and suvorexant (Belsomra) share dual orexin receptor antagonism but differ in approved doses, pharmacokinetics, trial programs, interaction language, and regional labeling; no network estimate makes one universally best.

Why this question matters

People often search by brand and encounter tables that imply a simple ranking. The clinically relevant choice also depends on sleep-onset versus maintenance symptoms, next-day function, age, liver function, respiratory disease, interacting CYP3A medicines, driving demands, cost, and country-specific approval. A comparison must use the generic name as the canonical entity and treat brands as search synonyms.

What evidence was reviewed

The core evidence consists of regulator-hosted prescribing information, placebo-controlled insomnia trials, extension studies, and systematic reviews or network meta-analyses. Labels provide the most reliable product-specific details. Network meta-analysis can compare treatments indirectly across different trials, but differences in participants, outcome definitions, dose, timing, and study duration reduce certainty.

What the studies found

All three medications improve selected sleep outcomes compared with placebo in approved populations. The magnitude differs by outcome and dose, and subjective and polysomnographic measures do not always move together. Their elimination profiles and next-day warnings differ, but a half-life table alone cannot predict morning impairment. Product labels also address complex sleep behaviors, driving, narcolepsy contraindication, CYP3A interactions, and use in respiratory or hepatic impairment.

Key limitations and sources of uncertainty

There are few direct head-to-head randomized comparisons. Trials often exclude severe sleep apnea, unstable psychiatric illness, substance-use disorders, complex polypharmacy, pregnancy, and many frail patients. Most outcomes are short term compared with years of real-world use. Indirect rank probabilities can exaggerate small, uncertain differences and should not be converted into “best DORA” claims.

What this may change in practice

Build a product comparison from current labels with columns for generic name, region, approved indication, dose range, CYP3A restrictions, half-life context, next-day precautions, and studied populations. Pair that with first-line CBT-I information. The final choice belongs to the prescriber and patient after reviewing comorbidities and goals.

What the evidence does not justify

The evidence does not justify substituting one DORA for another milligram-for-milligram, promising no next-day impairment, declaring a class-wide absence of withdrawal, or recommending a DORA solely because it ranks first in an indirect analysis.

What research should do next

Independent head-to-head trials should use patient-important outcomes such as daytime function, falls, driving, durable remission, and discontinuation effects. Longer pharmacovigilance and studies in cancer survivors, frailty, respiratory disease, and polypharmacy are priorities.

Funding and conflict-of-interest note

Drug-development studies are often sponsored by manufacturers, while guideline panels and independent reviews can also include authors with industry relationships. Publication should list the funding source and declared conflicts for every pivotal study. A declared conflict does not invalidate a result, but it raises the importance of protocol registration, complete outcome reporting, independent replication, and separation of evidence from promotional language.

When urgent medical assessment may be needed

    Seek urgent local medical assessment when any of the following applies. This list is intentionally conservative and is not a diagnostic checklist:

    - A trial result is described as proof for populations, durations, doses, or combinations that were not studied
  • Absence of a detected signal is rewritten as a categorical absence-of-risk claim

  • A network meta-analysis is presented as a head-to-head randomized comparison

  • Regulatory approval in one country is described as global approval

      Emergency pathways and telephone numbers vary by country. A tracking application or educational article cannot rule out an emergency.

Questions to take to the prescriber

  • Does this evidence apply to my diagnosis, age, treatment duration, formulation, and other medications?
  • Was the finding based on a randomized comparison, an indirect comparison, an observational study, or mechanistic modeling?
  • Were withdrawal, relapse, function, serious adverse events, and long-term outcomes measured directly?
  • What was not studied, and what uncertainty remains for my situation?
  • Would this finding actually change a clinical decision, or only support further research?

Frequently asked questions

Which DORA has the shortest half-life?

Pharmacokinetic profiles differ, but half-life alone does not determine next-day function or the best treatment.

Can the three medications be converted by dose?

No validated milligram-equivalence conversion should be assumed.

Are DORAs first-line for chronic insomnia?

Behavioral treatment, especially CBT-I, remains first-line in major guidelines. Medication choice is individualized.

Why use generic names in the article?

Generic names are stable across markets and research. Brand names are used once for search recognition, then the article uses the generic name consistently.

Regional and formulation note

Approval status, labels, and clinical practice vary by country. Verify the exact product label, manufacturer, strength, release system, and local clinical pathway before use. A tablet or capsule instruction that is correct for one product may be wrong for another.

References

  1. US prescribing information for daridorexant, lemborexant, and suvorexant. Evidence type: Regulator-hosted product labeling. Use in this article: Trial-based withdrawal and rebound assessments must not be rewritten as universal absence of risk.

  2. Network meta-analysis of dual orexin receptor antagonists for insomnia. 2025. Evidence type: Network meta-analysis. Use in this article: Indirect comparisons are not equivalent to head-to-head trials and must be interpreted with dose, duration, and outcome differences.

  3. American Academy of Sleep Medicine. Behavioral and psychological treatments for chronic insomnia disorder in adults. 2021. Evidence type: Clinical practice guideline. Use in this article: Strongly recommends multicomponent CBT-I for chronic insomnia; sleep hygiene alone is not equivalent to CBT-I.

Bring real data to your doctor
RxDown app

Bring real data to your doctor

Generate a clinician-ready Doctor Report in SBAR format with trend charts, plus clean CSV and PDF exports. Walk into your next appointment with evidence, not guesswork.

RxDown is a data tracking and journaling tool for adults (18+). It does not provide medical advice, diagnosis, or treatment. Never stop taking medication or change your dose based solely on information from this app or website — medication reduction should always be supervised by a qualified healthcare professional.